EAU updates guidelines on non-muscle-invasive bladder cancer

  • Eur Urol

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The European Association of Urology (EAU) has updated its guidelines on the management of non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS).

Key among the recommendations are the following:

  • TaT1 and/or CIS are grouped under the heading of NMIBC.
  • In papillary lesions, complete TURB is essential.
  • Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6  weeks.
  • The European Organisation for Research and Treatment of Cancer (EORTC) scoring system can be used to estimate risks of both recurrence and progression.
  • One immediate chemotherapy instillation is recommended for patients with tumours presumed to be at low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of
  • Patients with intermediate-risk tumours should receive 1  year of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1  year.
  • Full-dose intravesical BCG for 1-3 yr is indicated for patients with high-risk tumours.
  • In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered.
  • Cystectomy is recommended in BCG-unresponsive tumours.

The extended version of the guidelines is available here.